Trop2 CAR-T细胞疗法在肺腺癌治疗中的前景与挑战：从基础研究到临床转化
摘要
体内外研究中展示出显著的抗肿瘤活性，但其临床应用仍面临脱靶效应、肿瘤微环境影响等挑战，本综述提出了可
能的解决策略，为该疗法的临床转化提供了指导，并期待其能在更多肿瘤治疗中展现出显著的疗效。
关键词
全文:
PDF参考
[1]Chen L, Chen F, Li J, et al. CAR-T cell therapy
for lung cancer: Potential and perspective[J]. Thorac Cancer,
2022,13(7):889-899.DOI:10.1111/1759-7714.14375.
[2]Sun R, Hou Z, Zhang Y, et al. Drug resistance
mechanisms and progress in the treatment of EGFRmutated lung adenocarcinoma[J]. Oncol Lett, 2022,24(5):408.
DOI:10.3892/ol.2022.13528.
[3]Taromi S, Firat E, Simonis A, et al. Enhanced
AC133-specific CAR T cell therapy induces durable
remissions in mice with metastatic small cell lung
cancer[J]. Cancer Lett, 2022,538:215697.DOI:10.1016/
j.canlet.2022.215697.
[4]Qiu S, Zhang J, Wang Z, et al. Targeting Trop-2 in
cancer: Recent research progress and clinical application[J].
Biochim Biophys Acta Rev Cancer, 2023,1878(4):188902.
DOI:10.1016/j.bbcan.2023.188902.
[5]Wen Y, Ouyang D, Zou Q, et al. A literature review
of the promising future of TROP2: a potential drug therapy
target[J]. Ann Transl Med, 2022,10(24):1403.DOI:10.21037/
atm-22-5976.
[6]Holstein S A, Lunning M A. CAR T-Cell Therapy
in Hematologic Malignancies: A Voyage in Progress[J].
Clin Pharmacol Ther, 2020,107(1):112-122.DOI:10.1002/
cpt.1674.
[7]Huang J, Huang X, Huang J. CAR-T cell therapy
for hematological malignancies: Limitations and optimization
strategies[J]. Front Immunol, 2022,13:1019115.DOI:10.3389/
fimmu.2022.1019115.
[8]Schepisi G, Gianni C, Palleschi M, et al. The New
Frontier of Immunotherapy: Chimeric Antigen Receptor T
(CAR-T) Cell and Macrophage (CAR-M) Therapy against
Breast Cancer[J]. Cancers (Basel), 2023,15(5).DOI:10.3390/
cancers15051597.
[9]Lin Y J, Mashouf L A, Lim M. CAR T Cell Therapy
in Primary Brain Tumors: Current Investigations and the
Future[J]. Front Immunol, 2022,13:817296.DOI:10.3389/
fimmu.2022.817296.
[10]Chen Q, Lu L, Ma W. Efficacy, Safety, andChallenges of CAR T-Cells in the Treatment of Solid
Tumors[J]. Cancers (Basel), 2022,14(23).DOI:10.3390/
cancers14235983.
[11]Corti C, Venetis K, Sajjadi E, et al. CAR-T cell
therapy for triple-negative breast cancer and other solid
tumors: preclinical and clinical progress[J]. Expert Opin
Investig Drugs, 2022,31(6):593-605.DOI:10.1080/13543784.
2022.2054326.
[12]Esmaeilzadeh A, Hadiloo K, Jabbari M, et al.
Current progress of chimeric antigen receptor (CAR) T versus
CAR NK cell for immunotherapy of solid tumors[J]. Life Sci,
2024,337:122381.DOI:10.1016/j.lfs.2023.122381.
[13]Chen Q, Lu L, Ma W. Efficacy, Safety, and
Challenges of CAR T-Cells in the Treatment of Solid
Tumors[J]. Cancers (Basel), 2022,14(23).DOI:10.3390/
cancers14235983.
[14]Qiu S, Zhang J, Wang Z, et al. Targeting Trop-2
in cancer: Recent research progress and clinical application[J].
Biochim Biophys Acta Rev Cancer, 2023,1878(4):188902.
DOI:10.1016/j.bbcan.2023.188902.
[15]Ye F, Dewanjee S, Li Y, et al. Advancements in
clinical aspects of targeted therapy and immunotherapy in
breast cancer[J]. Mol Cancer, 2023,22(1):105.DOI:10.1186/
s12943-023-01805-y.
[16]Zheng Z, Li S, Liu M, et al. Fine-Tuning
through Generations: Advances in Structure and Production
of CAR-T Therapy[J]. Cancers (Basel), 2023,15(13).
DOI:10.3390/cancers15133476.
[17]Yang Y H, Liu J W, Lu C, et al. CAR-T Cell
Therapy for Breast Cancer: From Basic Research to Clinical
Application[J]. Int J Biol Sci, 2022,18(6):2609-2626.
DOI:10.7150/ijbs.70120.
[18]Balagopalan L, Moreno T, Qin H, et al. Generation
of antitumor chimeric antigen receptors incorporating T
cell signaling motifs[J]. Sci Signal, 2024,17(846):eadp8569.
DOI:10.1126/scisignal.adp8569.
[19]Patel S R, Das M. Small Cell Lung Cancer:
Emerging Targets and Strategies for Precision Therapy[J].
Cancers (Basel), 2023,15(16).DOI:10.3390/cancers15164016.
[20]李博乐，冯红蕾，魏枫，等.肿瘤抗体药物偶联
物的研发进展和挑战[J].中国肿瘤临床，2022，49（16）：
850-857.
Refbacks
- 当前没有refback。
